ArticleFrontiers in immunology2025
Case Report: An unexpected case of tumor regression in blue nevus melanoma following COVID-19 infection.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Blue nevus is a benign melanocytic lesion that appears as a blue or dark mole due to the presence of melanin deep within the skin. In rare cases melanoma can arise from this association with blue nevus, and entity termed blue nevus melanoma (BNM). BNM most frequently occurs on the scalp and is an aggressive subtype of melanoma which has the tendency to metastasize. Similar to acral melanoma, BNM has a distinct genetic profile, is less linked to sun exposure, and has an equal incidence in patients of European and non-European ancestry. It is also less responsive to immunotherapy. This case report describes a diagnosis of blue nevus-related scalp melanoma characterized by GNA11 mutation in a 50-year-old female Hispanic patient, with a tumor refractory to multiple courses of combination immunotherapy who developed metastases to the liver and underwent microwave ablation of the hepatic lesions. Her disease course was complicated by hospitalization for infection with coronavirus disease of 2019 (COVID-19) and autoimmune hepatitis. Months after being discharged, surveillance imaging revealed a decrease in size of the existing lesions without additional therapeutic intervention. While this unusual response can be attributed to multiple factors, this observation aligns with emerging reports suggesting potential tumor remission associated with COVID-19 infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.